A 38-year-old man with severe immunosuppression (CD4 count 15 cells/μL) presents with progressive cytomegalovirus (CMV) retinitis. He has been on intravenous ganciclovir for 3 weeks with clinical failure. Which finding best distinguishes ganciclovir-resistant CMV from ganciclovir-sensitive CMV in this patient?

Explanation

## Distinguishing Ganciclovir-Resistant CMV: The Role of UL97 Phosphotransferase **Key Point:** The **most common** mechanism of ganciclovir resistance in CMV is **deficiency or mutation of the viral phosphotransferase encoded by the UL97 gene**, which is responsible for the initial (rate-limiting) phosphorylation of ganciclovir to ganciclovir monophosphate. ### Mechanism of Ganciclovir Activation and Resistance Ganciclovir is a prodrug that requires sequential phosphorylation: 1. **UL97 kinase** → ganciclovir monophosphate (rate-limiting step, CMV-specific) 2. Cellular kinases → ganciclovir diphosphate → ganciclovir triphosphate (active form) 3. Ganciclovir triphosphate inhibits **UL54 (viral DNA polymerase)** ### Two Mechanisms of CMV Ganciclovir Resistance | Mechanism | Gene | Frequency | Cross-Resistance | Clinical Significance | |-----------|------|-----------|------------------|----------------------| | **UL97 kinase mutation** | UL97 | **~70–80% of resistant isolates** | Sensitive to foscarnet & cidofovir | Most common; prodrug activation defect | | **UL54 DNA polymerase mutation** | UL54 (not UL30*) | ~20–30% | May cross-resist foscarnet & cidofovir | Less common; true target-enzyme resistance | *Note: CMV DNA polymerase is encoded by **UL54**, not UL30 (UL30 is the HSV DNA polymerase gene). Option A contains a factual error in gene nomenclature, further disqualifying it. **High-Yield (KD Tripathi / Mandell's Principles):** UL97 mutations account for the **majority** of clinically encountered ganciclovir resistance. The question asks what "best distinguishes" ganciclovir-resistant from ganciclovir-sensitive CMV — the hallmark finding is **absence or dysfunction of UL97 phosphotransferase**, since this enzyme is uniquely required for ganciclovir activation in CMV-infected cells and is absent in sensitive strains that have been exposed to selection pressure. ### Why Option D (UL97 Deficiency) Is Correct 1. **Most frequent resistance mechanism** (~70–80% of resistant isolates per Mandell's) 2. **Mechanistically specific** — UL97 is the CMV-specific kinase; its deficiency is the defining molecular event that separates resistant from sensitive strains 3. **Clinically actionable** — UL97-deficient strains remain susceptible to foscarnet and cidofovir, guiding treatment switch 4. **Genotypic testing** for UL97 mutations is the standard diagnostic approach for confirmed ganciclovir resistance ### Why Option A Is Incorrect - Option A incorrectly attributes CMV DNA polymerase to the **UL30 gene** (UL30 encodes HSV-1 DNA polymerase; CMV DNA polymerase is **UL54**) - UL54 mutations are a secondary, less common resistance mechanism - Even setting aside the gene nomenclature error, UL97 mutations are more frequent and are the primary distinguishing feature **Clinical Pearl:** In a patient with clinical failure after 3 weeks of IV ganciclovir, genotypic resistance testing targeting **UL97** should be performed first. If UL97 is wild-type, UL54 should be sequenced. Foscarnet is the preferred salvage agent for UL97-mutant CMV retinitis. **Mnemonic:** **UL97 = UPTAKE FAILURE** — CMV cannot activate the prodrug → resistance without touching the polymerase target.